openPR Logo
Press release

Global Primary Biliary Cholangitis Treatment Market is Driven by Rise in Incidence of Primary Biliary Cholangitis

01-25-2017 06:41 AM CET | Health & Medicine

Press release from: TMR

Global Primary Biliary Cholangitis Treatment Market is Driven

Primary biliary cholangitis, previously known as primary biliary cirrhosis, is a rare chronic liver disease, primarily characterized by destruction of the bile ducts which transport bile acid out of the liver. Although the primary cause of the disease has not yet been elucidated, research across the world has attributed it to be autoimmune in nature. The progress of this disease results in the harmful accumulation of bile acid, which causes severe liver damage, resulting in cirrhosis at the later stage of the disease. The disease primarily affects women in their middle age. The lack of a definitive cure for primary biliary cholangitis (PBC) results in an immensely lucrative business opportunity to tap into this underserved market.

Request a PDF Brochure with Report Analysis: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14093

Although presently the disease cannot be cured by medication, the progression of liver damage can be stalled with the help of a drug known as ursodeoxycholic acid (UDCA), the only FDA approved medication for the disease. Additionally, the symptoms of the disease in early stages which include itching and fatigue can be relieved with the aid of drugs such as antihistamines and opioid antagonists. However, if primary biliary cholangitis is diagnosed in later stages, the sole treatment option which remains viable for survival is liver transplantation.

The improved diagnostic processes worldwide coupled with rise in patient awareness regarding treatment and physician check-ups upon experiencing symptomatic discomfort has led to lesser requirement of transplants. The improved scenario relating to the prognosis of primary biliary cholangitis has thus made medication a more popular course of treatment in comparison to liver transplants resulting in alleviating the progression of the disease.

Although the treatment with UDCA helps reduce advancement of liver destruction, the drug has shown to be ineffective in adequately reducing disease specific blood compounds (such as bilirubin) in over 40% patients. Moreover few patients have experienced intolerance to the drug. Thus, there is immense potential for a new cure and innovative drug to create a remedial breakthrough in the market due to the current unmet need of the patient population.

The global primary biliary cholangitis market can been segmented on the basis of type of treatment and by region. Based on type of treatment, the global market has been segmented into drugs and liver transplantation. The drugs segment has been further segmented into primary treatment (UDCA) and symptomatic relief treatment. The symptomatic relief segment includes drugs to aid in reduction of disease symptoms which includes antihistamines, Cholestyramine, antibacterials and opioid antagonists. In addition, a pipeline assessment has also been provided to assess the drugs undergoing early stage and late stage clinical trials.

Globally, the annual incidence of the disease is estimated to be between 0.7 and 49 cases per million-population and prevalence between 6.7 and 940 cases per million-population, the variance in cases primarily based on age and gender and geographic location. However, various peer reviewed articles have suggested that the incidence is gradually increasing worldwide. Geographically the market has been segmented into five regions, namely North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The market for this disease is expected to be higher in North America and Europe owing to the higher prevalence and incidence of the disease in those regions.

Primary Biliary Cholangitis is more prevalent in Northern Europe, North America and Latin America and less common in Eastern Asia, Africa, and Australia. In the U.S., PBC is among the top ten causes to undergo a liver transplant. The incidence of PBC is high in U.K as compared to other regions in Europe and thus U.K is an attractive business opportunity for research as well as trial studies and drug sales pertaining to this disease. Thus, the global market for PBC is driven by rise in incidence of primary biliary cholangitis, increased exposure to environmental triggers to the immune system such as pesticides to susceptible individuals and growth in faulty lifestyle related triggers such as alcoholism, smoking and obesity.

Browse Full Research Report: http://www.transparencymarketresearch.com/primary-biliary-cholangitis-treatment-market.html

The key players in the market include Novartis AG, Actavis, Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals, Lumena Pharmaceuticals, Inc., Siedco Pharmaceutical Co., and Teva Pharmaceuticals Inc. etc.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Primary Biliary Cholangitis Treatment Market is Driven by Rise in Incidence of Primary Biliary Cholangitis here

News-ID: 420405 • Views: 584

More Releases from TMR

Hot Sauce Market 2022 Outlook, Current and Future Industry Landscape Analysis 20 …
The global Hot Sauce market is estimated to attain a valuation of US$ 15.0 Bn by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 5% during the forecast period, 2022-2031. The key objective of the TMR report is to offer a complete assessment of the global market including major leading stakeholders of
Specialty Fats & Oils Market Research Elaborate Analysis with Growth Forecast to …
The global Specialty Fats & Oils market is estimated to attain a valuation of US$ 23.7 Bn by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 5.9% during the forecast period, 2022-2031. The key objective of the TMR report is to offer a complete assessment of the global market including major leading
Building Analytics Market Size, Business Revenue Forecast, Leading Competitors a …
The global Building Analytics market is estimated to attain a valuation of US$ 20.1 Bn by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 15% during the forecast period, 2021-2031. The key objective of the TMR report is to offer a complete assessment of the global market including major leading stakeholders of
Metal Cleaning Equipment Market Growth Probability, Leading Vendors and Future S …
The global Metal Cleaning Equipment market is estimated to attain a valuation of US$ 1.35 Bn by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 3.8% during the forecast period, 2022-2031. The key objective of the TMR report is to offer a complete assessment of the global market including major leading stakeholders

All 5 Releases


More Releases for Primary

Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include: 1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk
Global Primary Sclerosing Cholangitis Market
The Primary Sclerosing Cholangitis report offers insights into vital aspects like growth,CAGR value, market share and revenue analysis. It evaluates the growth opportunities, threats, market drivers and risks involved. understand the market competition by analyzing the top vendors, with their market profile, revenue, profits, import-export details, and market share. it states the pricing structure, import-export details, supply chain analysis, SWOT analysis to facilitate the key decision-making process. This report helps
Primary Lithium Battery (Primary Lithium Batteries) Industry Analysis by 2025:  …
In its recently published report, QY Research has provided unique insights about global Primary Lithium Battery (Primary Lithium Batteries) market for the given period. One of the main objectives of this report is to categorize the various dynamics of the market and to offer latest updates such as mergers and acquisitions, various technological developments, new entrants in the market, which make an impact on different segments of the global Primary
Primary Cells And Primary Batteries Market Analysis by Production Capacity, Dyna …
This report helps to analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Primary Cells And Primary Batteries market. Description The Global Primary Cells And Primary Batteries Market report offers a comprehensive evaluation of the Global Primary Cells And Primary Batteries industry. This report evaluates the Global market for " Global Primary Cells And Primary Batteries". The Global Primary Cells
Primary Immunodeficiency Diseases Market: Key Insights
With only a handful of companies enjoying the major share of the revenue pie, the global primary immunodeficiency diseases (PIDD) market exhibits a consolidated vendor landscape. As per Transparency Market Research (TMR), CSL Behring LLC and Grifols S.A. emerged dominant in the market with a share of 60.5% in 2014. Baxter International, Inc. and Octapharma AG are other prominent enterprises operating in the global PIDD market. These companies have been
Primary Packaging Market is driven With Demand for Primary Packaging Products fr …
Primary packaging is the layer of packaging which is in immediate contact with the product or it is the first packaging layer in which the product is enclosed. Primary packaging has diverse range of applications and functions, depending on the type product, mode of transport and storage facilities. The most important function of primary packaging is to protect and preserve the product from external damage, contamination and spoiling. Primary packaging